Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 4,918 recruiting studies in this area right now.
By phase
- Not applicable2,022
- Phase 21,072
- Phase 1792
- Phase 1/Phase 2478
- Phase 3345
- Phase 4126
- Phase 2/Phase 383
Top conditions
- Multiple Myeloma327
- Acute Myeloid Leukemia281
- Lymphoma178
- Sickle Cell Disease134
- Myelodysplastic Syndromes128
- Acute Lymphoblastic Leukemia118
- Leukemia100
- Chronic Lymphocytic Leukemia95
- Follicular Lymphoma70
- Hematologic Malignancy67
- Myelodysplastic Syndrome64
- Hodgkin Lymphoma63
- Mantle Cell Lymphoma62
- Anemia56
- Diffuse Large B Cell Lymphoma54
- Malignant Solid Neoplasm53
- Acute Myeloid Leukemia (AML)48
- Lymphedema48
Leading sponsors
- M.D. Anderson Cancer Center145
- Institute of Hematology & Blood Diseases Hospital, China138
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University67
- Memorial Sloan Kettering Cancer Center63
- City of Hope Medical Center58
- Mayo Clinic55
- Assistance Publique - Hôpitaux de Paris45
- St. Jude Children's Research Hospital44
- Peking University People's Hospital43
Where studies are running
- California396
- Texas185
- Alabama156
- Maryland152
- Arizona125
- Florida105
- Massachusetts103
- New York98
- Ohio70
- Minnesota69
Recruiting studies4,918 total
- NCT07708714RecruitingPhase 1/Phase 2
Hydroxyurea study for teens with sickle cell anemia
This study tests how well a higher dose of hydroxyurea works for teenagers with sickle cell anemia living in areas where malaria is common. It looks at safety and how the treatment affects their daily lives.
KampalaAges 11–18 - NCT07710534RecruitingPhase 2
A study of decitabine-cedazuridine and venetoclax for blood cancers
This trial tests a combination of two drugs (decitabine-cedazuridine and venetoclax) that are given in a low-dose, frequent schedule (metronomic) for people with certain blood cancers that have come back or not responded to treatment. The goal is to see if this combo can help control the disease.
Richmond, VirginiaAges 18 years+ - NCT07707817Recruiting
Expanding preventive medicine access for mobile groups
This study tests whether giving preventive medicine to people who move or migrate can help control river blindness and lymphatic filariasis. It focuses on children and household heads who have missed past treatment rounds.
Ondo, Ondo, Taraba and Akwa IbomAges 5 years+ - NCT07709013RecruitingPhase 2
Leflunomide to stop CMV after stem cell transplant
This study tests whether the drug leflunomide can prevent CMV virus reactivation after a half-matched stem cell transplant. If you have already had a successful white blood cell recovery and no sign of CMV, this might help keep you safe from the virus.
Navi Mumbai, MaharashtraAges 18 years+ - NCT06642025RecruitingEarly Phase 1
EX02 car-t cells for hard-to-treat acute myeloid leukemia
This trial tests a new treatment called EX02 CAR-T cells for people with acute myeloid leukemia (AML) that has come back or not responded to standard treatments. The therapy uses your own immune cells, modified to target a specific marker on leukemia cells, to help fight the cancer.
Hefei, AnhuiAges 18–70 - NCT06644443RecruitingPhase 1/Phase 2
BCMA-GPRC5D CAR-T cells for relapsed multiple myeloma
This trial tests a new kind of immunotherapy that uses your own immune cells, called CAR-T cells, to target two specific markers (BCMA and GPRC5D) found on myeloma cells. It's for people whose multiple myeloma has come back or stopped responding to earlier treatments.
Shenzhen, GuangdongAges 18–75 - NCT06625372Recruiting
Comparing two IV nutrition options for children after stem cell transplant
This study compares two types of IV nutrition (Intralipid and SMOF Lipid) for children undergoing stem cell transplants for leukemia. It aims to find which option is better for helping them recover.
TehranAges 2–18 - NCT05683886RecruitingPhase 2
Study KC1036 for advanced thymus tumors after chemotherapy
This trial tests KC1036 in people with advanced thymoma or thymic carcinoma whose cancer came back or spread after their first standard chemotherapy. It may offer a new treatment option when earlier treatment no longer worked.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07700238RecruitingPhase 3
Romiplostim plus steroids vs steroids alone for newly diagnosed ITP
This trial tests if adding romiplostim (a drug that helps make platelets) to standard steroid treatment works better than steroids alone for adults who have not been treated for ITP before. It is for people with low platelet counts and may help reduce bleeding.
Long Beach, CaliforniaAges 18–100 - NCT07705178Recruiting
MRI study of heart and lung health after childhood cancer
This study uses MRI scans to look at the heart and lungs of childhood cancer survivors to see if chemotherapy caused any long-term changes. It may help doctors better understand and manage late effects after treatment for leukemia or lymphoma.
ErlangenAges 3 years+ - NCT07699016Recruiting
Hemostatic agent use in heart and blood vessel surgery
This trial surveys surgeons about how they use hemostatic agents (medications that stop bleeding during surgery). It aims to understand current practices and improve patient safety.
Milan, MIAges 18 years+ - NCT07699666Recruiting
Cord clamping timing for preterm babies
This study compares waiting a bit before clamping the umbilical cord versus clamping it right away for babies born between 32 and 37 weeks of pregnancy. It helps determine which approach may be better for preterm infants.
Tunis, Tunis GovernorateAges birth+ - NCT07702916Enrolling by invitation
Hygiene and menstruation study for girls in Madagascar
This trial looks at how hygiene and menstrual health programs affect learning and emotional well-being. If you are a girl in the Kilonga 2 study, you may be asked to complete surveys and some tests, and possibly provide saliva or blood samples.
AntananarivoAges 11–21 - NCT05386277Recruiting
Testing safety of an embolectomy catheter used during clot surgery
This study follows patients who are having surgery to remove a blood clot in an artery or vein and where a specific clot-removal catheter (the LeMaitre TufTex Single Lumen) is used. It aims to confirm how well the device works and monitor safety outcomes.
GenkAges 18 years+ - NCT05546723RecruitingPhase 1
Study drug for multiple myeloma after several prior treatments
This Phase 1 trial tests LMY-920 in people with multiple myeloma that has returned or stopped responding after multiple standard therapies. It’s meant to see if the treatment can work and to better understand its safety and side effects in this situation.
Cleveland, OhioAges 18 years+ - NCT05725265Recruiting
Low-level laser treatment for arm swelling after breast cancer
This study tests whether low-level laser therapy can safely reduce swelling in one arm caused by breast-cancer treatment. It compares the laser to a look-alike inactive (placebo) treatment and checks changes over time.
TaipeiAges 20 years+ - NCT05312801RecruitingPhase 1
Testing BAFF CAR-T for relapsed or resistant non-Hodgkin lymphoma
This Phase 1 study tests a new immune cell treatment (BAFF CAR-T) for people with non-Hodgkin lymphoma that has come back or did not respond well to treatment. It aims to see how safe it is and whether it can help control the lymphoma.
Cleveland, OhioAges 18 years+ - NCT05726110RecruitingPhase 3
Selinexor for relapsed or refractory AML in combination treatments
This Phase 3 trial studies selinexor (a medicine that changes signals inside cancer cells) used together with other leukemia treatment regimens for adults whose acute myeloid leukemia (AML) has come back or did not respond to standard therapy. It may help people reach remission or control the disease better than the current approach.
Taiyuan, ShanxiAges 18–60 - NCT04587856Recruiting
Study why blood cancer returns after donor stem cell transplant
This study looks at why a bone marrow disorder (MDS) can come back after a donor stem cell transplant. It may help researchers understand relapse, which could improve future care for people getting transplants.
BariAges 18 years+ - NCT07690761Enrolling by invitationPhase 2
Rituximab and Zanubrutinib for hairy cell leukemia
This trial tests a combination of two targeted drugs, rituximab and zanubrutinib, for people with hairy cell leukemia or its variant. It aims to see if this therapy works for those who have already had one type of chemotherapy or who cannot take a standard treatment called purine analogs.
HaifaAges 18 years+ - NCT07689058RecruitingPhase 2
CAR-T therapy for relapsed or refractory multiple myeloma
This trial tests a CAR-T cell therapy for multiple myeloma that has come back or not responded to at least three prior treatments. It aims to see if this immunotherapy can help control the disease.
Rawalpindi, Punjab ProvinceAges 18 years+ - NCT07695012RecruitingEarly Phase 1
CAR-T cell therapy for B-cell acute lymphoblastic leukemia
This trial tests a personalized cell therapy (CAR-T) for people with B-cell acute lymphoblastic leukemia (ALL) that has come back after treatment or is hard to treat. The therapy uses your own immune cells, modified to find and kill leukemia cells.
RawalpindiAges 5–50 - NCT07691606RecruitingPhase 1
Testing a new drug for B-cell lymphoma that has come back
This trial tests a new medicine called ARC-02 for people with certain types of B-cell non-Hodgkin lymphoma (a cancer of the immune system) that has not responded well enough to at least two prior treatments. The goal is to see if this drug can help when other options are no longer working.
Los Angeles, CaliforniaAges 18 years+ - NCT06647940RecruitingPhase 2
Orelabrutinib plus R-CHOP for CD5-positive DLBCL
This trial tests whether adding a targeted therapy called orelabrutinib to standard chemotherapy (R-CHOP) helps people with a specific type of fast-growing lymphoma (CD5-positive DLBCL). If you have this lymphoma and haven't had a BTK inhibitor before, this combination might work better than chemo alone.
Guangzhou, ChinaAges 18 years+
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 4,918 recruiting hematology studies from the U.S. registry right now, out of 7,266 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.